OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 26,145 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 105.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,897 shares of the company's stock after buying an additional 26,145 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.13% of Keros Therapeutics worth $806,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Braidwell LP grew its stake in shares of Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock valued at $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Lynx1 Capital Management LP acquired a new stake in shares of Keros Therapeutics in the 4th quarter valued at approximately $8,612,000. Millennium Management LLC raised its holdings in Keros Therapeutics by 53.3% in the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after buying an additional 305,169 shares during the last quarter. Boxer Capital Management LLC bought a new position in Keros Therapeutics during the 4th quarter worth approximately $3,958,000. Finally, Integral Health Asset Management LLC increased its stake in shares of Keros Therapeutics by 125.0% in the 4th quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company's stock valued at $7,124,000 after acquiring an additional 250,000 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 20.60% of the company's stock.

Keros Therapeutics Trading Down 0.1%

Shares of KROS traded down $0.02 during midday trading on Monday, hitting $14.05. The stock had a trading volume of 182,047 shares, compared to its average volume of 833,439. The business has a 50-day simple moving average of $12.43 and a two-hundred day simple moving average of $22.62. The firm has a market cap of $570.64 million, a P/E ratio of -2.69 and a beta of 1.32. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. During the same period in the previous year, the business posted ($1.21) earnings per share. On average, analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on KROS shares. Truist Financial cut their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Scotiabank reduced their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. Finally, Wedbush reissued a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $37.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.